Equillium (EQ) Price & Analysis

Compare

739 Followers

EQ Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.27 - $2.26

Previous CloseN/A

Volume484.47K

Average Volume (3M)15.47M

Market Cap

$113.06M

Enterprise Value$22.73K

Total Cash (Recent Filing)$11.49M

Total Debt (Recent Filing)$259.00K

Price to Earnings (P/E)―

Beta-0.04

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding59,503,223

10 Day Avg. Volume29,727,805

30 Day Avg. Volume15,468,925

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$4.00

Price Target Upside110.53% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

FinancingThe private placement of up to $50 million accelerates the advancement of EQ504 into a Phase 1 proof-of-concept trial, reflecting renewed investor interest.

Investor SentimentThe private placement represents a fundamental positive for EQ shares, indicating investor optimism for AhR modulators as a promising class of therapeutics.

Product DevelopmentEQ504's convenient oral administration and differentiated barrier repair-focused mechanism of action are seen as drivers for differentiation versus existing treatments.

Bears Say

Clinical Trial ResultsThe EQUATOR trial failed to achieve its primary endpoint of complete response at Day 29 and both key secondary endpoints.

Financial OverhangA financing solution remains a significant near-term overhang for EQ shares.

Regulatory ChallengesThe FDA declined to support an accelerated approval pathway for itolizumab in first-line treatment of acute graft-versus-host disease.

Equillium News

Equillium price target lowered to $4 from $8 at Jefferies

Jefferies lowered the firm’s price target on Equillium (EQ) to $4 from $8 and keeps a Buy rating...

6d ago

3 Penny Stocks to Watch Now, 8/12/25

Equillium, Bluejay Diagnostics, and Entero Therapeutics are the 3 Penny Stocks to watch on August 12, 2025, based on TipRanks’ Penny...

15d ago

BJDX

Equillium Stock (EQ) Rockets 140% on $50M Private Placement

Equillium stock soared on Monday after the company announced a $50 million private placement. ...

15d ago

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Monday is here and with it comes loads of stock market stories that traders need to start the week with! ...

16d ago

Equillium announces strategic expansion of cryptocurrency treasury strategy

Equillium (EQ) announced a strategic expansion to integrate a cryptocurrency treasury reserve strategy as part of its broader...

23d ago

Equillium’s Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial Uncertainties

Leerink Partners analyst Thomas Smith has maintained their neutral stance on EQ stock, giving a Hold rating on...

12d ago

Equillium Secures $30 Million in Private Placement

Equillium ( ($EQ) ) has issued an update. On August 10, 2025, Equillium, Inc. entered into a Securities...

16d ago

Equillium Announces Strategic Shift in Sales Agent

Equillium ( ($EQ) ) just unveiled an announcement. On August 3, 2025, Equillium announced a strategic shift by...

23d ago

Equillium Granted Extension for Nasdaq Compliance

Equillium ( ($EQ) ) has shared an announcement. Equillium, Inc. received a notice from Nasdaq on December 13,...

2M ago

Equillium Holds Annual Stockholders Meeting on Key Proposals

Equillium ( ($EQ) ) just unveiled an update. On May 21, 2025, Equillium, Inc. held its Annual Meeting...

3M ago

Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’

Leerink notes that Equillium (EQ) announced that the FDA declined to support an accelerated approval pathway for itolizumab...

4M ago

Equillium says FDA declines Breakthrough Therapy designation for itolizumab

Equillium (EQ) announced that the company has received feedback from its Type D meeting with the FDA to...

4M ago

Equillium’s Hold Rating: Clinical and Financial Challenges Amid Uncertain Regulatory Pathway

Leerink Partners analyst Thomas Smith downgraded the rating on Equillium (EQ – Research Report) to a Hold today,...

5M ago

Equillium downgraded to Market Perform from Outperform at Leerink

Leerink analyst Thomas Smith downgraded Equillium (EQ) to Market Perform from Outperform with a price target of $1,...

5M ago

EQ FAQ

What was Equillium Inc’s price range in the past 12 months?

Equillium Inc lowest stock price was $0.27 and its highest was $2.26 in the past 12 months.

What is Equillium Inc’s market cap?

Equillium Inc’s market cap is $113.06M.

When is Equillium Inc’s upcoming earnings report date?

Equillium Inc’s upcoming earnings report date is Nov 18, 2025 which is in 83 days.

How were Equillium Inc’s earnings last quarter?

Equillium Inc released its earnings results on Aug 05, 2025. The company reported -$0.161 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.001.

Is Equillium Inc overvalued?

According to Wall Street analysts Equillium Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Equillium Inc pay dividends?

Equillium Inc does not currently pay dividends.

What is Equillium Inc’s EPS estimate?

Equillium Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Equillium Inc have?

Equillium Inc has 59,503,223 shares outstanding.

What happened to Equillium Inc’s price movement after its last earnings report?

Equillium Inc reported an EPS of -$0.161 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went up 7.143%.

Which hedge fund is a major shareholder of Equillium Inc?

Currently, no hedge funds are holding shares in EQ

Equillium Stock Smart Score

Neutral

Fundamentals

Return on Equity

-146.92%

Trailing 12-Months

Asset Growth

-71.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Equillium Inc

Equillium, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for severe autoimmune and inflammatory diseases. The company specializes in the discovery and development of unique monoclonal antibody treatments that target specific immune pathways, aimed at addressing unmet medical needs in various chronic conditions. Equillium's core products are centered around its proprietary drug candidates, including those targeting disorders such as alopecia areata and other severe inflammatory conditions.

Equillium (EQ) Earnings & Revenues

Historic Earnings Reports

EQ Stock 12 Month Forecast

Average Price Target

$4.00

▲(110.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.963076923076923,1.2161538461538461,1.4692307692307693,1.7223076923076923,1.9753846153846153,2.2284615384615387,2.4815384615384617,2.7346153846153847,2.9876923076923076,3.2407692307692306,3.493846153846154,3.746923076923077,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.963076923076923,1.2161538461538461,1.4692307692307693,1.7223076923076923,1.9753846153846153,2.2284615384615387,2.4815384615384617,2.7346153846153847,2.9876923076923076,3.2407692307692306,3.493846153846154,3.746923076923077,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.963076923076923,1.2161538461538461,1.4692307692307693,1.7223076923076923,1.9753846153846153,2.2284615384615387,2.4815384615384617,2.7346153846153847,2.9876923076923076,3.2407692307692306,3.493846153846154,3.746923076923077,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >